Alvotech said in a Monday press release it has appointed Joseph Edward McClellan as its new Chief Scientific Officer, who will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.
Alvotec describes McClellan as a professional with an outstanding track record in drug development with broad experience in all areas of biopharmaceutical development, including biosimilars, innovator biologics, pharmaceutical science, clinical development, regulatory strategy and discovery research.
Prior to joining Alvotech, McClellan worked with Pfizer for 17 years in various capacities, including Global Head of Biosimilars Development and Medicine/Asset Team Leader of IXIFI (biosimilar infliximab), Alvotech said.
McClellan is seen as a great asset to Alvotech’s team since he is an insightful scientist and a proven leader with a track record in driving forward end-to-end biopharmaceutical development programs, whilst ensuring strategic, scientific and operational excellence, the company’s press release reads.
Alvotech’s CEO Mark Levick said: “(McClellan) has every confidence that McClellan’s “invaluable experience in the pharmaceutical industry will be of great strategic value to Alvotech. His dynamic approach and impressive leadership skills make him an ideal addition to our team.”